PVR and cancer: CD112 binds TIGIT and CD226 less strong than CD155, and does not bind CD96.96,112 CD111 only interacts with and stabilizes CD155.113 Nectin-4 only interacts with TIGIT.114 These preferences bring about competitive binding dynamics, explaining the mechanism of immunosuppression mediated by this network-like pathway in cancers.